Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8+ T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model

Cancer Immunology, Immunotherapy

Volumn 63, Issue 4, 2014, Pages 321-333

  Bauer, Christian ^a   Sterzik, Alexander ^a   Bauernfeind, Franz ^a   Duewell, Peter ^a   Conrad, Claudius ^d   Kiefl, Rosemarie ^a   Endres, Stefan ^a   Eigler, Andreas ^c   Schnurr, Max ^a   Dauer, Marc ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b St Elisabeth Klinik   (Germany)

^c Klinikum Dritter Orden   (Germany)

^d HARVARD UNIVERSITY   (United States)

Author keywords

Chemotherapy; Dendritic cells; Gemcitabine; Pancreatic carcinoma; Survival; Vaccination

Indexed keywords

CANCER ANTIBODY; CANCER VACCINE; DENDRITIC CELL VACCINE; GEMCITABINE; OVA DC VACCINE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CELL MIGRATION; CELLULAR IMMUNITY; CHEMOSENSITIZATION; CHRONOTHERAPY; CONTROLLED STUDY; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY ASSAY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; REVACCINATION; TREATMENT OUTCOME; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; ANTIBODY SPECIFICITY; ANTIMETABOLITES, ANTINEOPLASTIC; B-LYMPHOCYTES; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DENDRITIC CELLS; DEOXYCYTIDINE; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOSUPPRESSION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OVALBUMIN; PANCREATIC NEOPLASMS; PEPTIDE FRAGMENTS; TUMOR ESCAPE;

EID: 84896492317     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-013-1510-y     Document Type: Article

References (43)

1. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403-2413 (Pubitemid 27251144)
2. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, Andre T, Zaniboni A, Ducreux M, Aitini E, Taieb J, Faroux R, Lepere C, de Gramont A (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23(15):3509-3516
3. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M (2011) Folfirinox versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817-1825. doi:10.1056/NEJMoa1011923
4. Fukunaga A, Miyamoto M, Cho Y, Murakami S, Kawarada Y, Oshikiri T, Kato K, Kurokawa T, Suzuoki M, Nakakubo Y, Hiraoka K, Itoh T, Morikawa T, Okushiba S, Kondo S, Katoh H (2004) CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 28(1):e26-e31
5. Schmitz-Winnenthal FH, Volk C, Z'Graggen K, Galindo L, Nummer D, Ziouta Y, Bucur M, Weitz J, Schirrmacher V, Buchler MW, Beckhove P (2005) High frequencies of functional tumor-reactive t cells in bone marrow and blood of pancreatic cancer patients. Cancer Res 65(21):10079-10087 (Pubitemid 41541490)
6. Bauer C, Dauer M, Saraj S, Schnurr M, Bauernfeind F, Sterzik A, Junkmann J, Jakl V, Kiefl R, Oduncu F, Emmerich B, Mayr D, Mussack T, Bruns C, Ruttinger D, Conrad C, Jauch KW, Endres S, Eigler A (2011) Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study. Cancer Immunol Immunother 60(8):1097-1107. doi:10.1007/s00262-011-1023-5
7. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, Pineiro L, Steinman R, Fay J (2001) Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61(17):6451-6458 (Pubitemid 32783251)
8. Correale P, Aquino A, Giuliani A, Pellegrini M, Micheli L, Cusi MG, Nencini C, Petrioli R, Prete SP, De Vecchis L, Turriziani M, Giorgi G, Bonmassar E, Francini G (2003) Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLAA(*) 02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro. Int J Cancer 104(4):437-445 (Pubitemid 36323913)
9. Bauer C, Bauernfeind F, Sterzik A, Orban M, Schnurr M, Lehr HA, Endres S, Eigler A, Dauer M (2007) Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model. Gut 56(9):1275-1282 (Pubitemid 47300430)
10. Hou JM, Liu JY, Yang L, Zhao X, Tian L, Ding ZY, Wen YJ, Niu T, Xiao F, Lou YY, Tan GH, Deng HX, Li J, Yang JL, Mao YQ, Kan B, Wu Y, Li Q, Wei YQ (2005) Combination of low-dose gemcitabine and recombinant quail vascular endothelial growth factor receptor-2 as a vaccine induces synergistic antitumor activities. Oncology 69(1):81-87 (Pubitemid 41207061)
11. Nowak AK, Robinson BW, Lake RA (2003) Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 63(15):4490-4496 (Pubitemid 36951021)
12. Plate JM, Plate AE, Shott S, Bograd S, Harris JE (2005) Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother 54(9):915-925 (Pubitemid 40991334)
13. Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ, Frelinger JA, Robinson BW (2003) Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, crosspriming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 170(10):4905-4913 (Pubitemid 36554719)
14. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM (2005) Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 11(18):6713-6721 (Pubitemid 41339014)
15. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S (2007) Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 179(2):977-983
16. Hogquist KA, Jameson SC, Bevan MJ (1994) The ligand for positive selection of T lymphocytes in the thymus. Curr Opin Immunol 6(2):273-278 (Pubitemid 24106825)
17. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR (1994) T cell receptor antagonist peptides induce positive selection. Cell 76(1):17-27 (Pubitemid 24035278)
18. Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold DP Jr, Schabel FM Jr (1984) Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57Bl/6 mice. Cancer Res 44(2):717-726 (Pubitemid 14184610)
19. Schmidt T, Ziske C, Marten A, Endres S, Tiemann K, Schmitz V, Gorschluter M, Schneider C, Sauerbruch T, Schmidt-Wolf IG (2003) Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57bl/6 pancreatic murine tumor model. Cancer Res 63(24):8962-8967 (Pubitemid 38064077)
20. Jacobs C, Duewell P, Heckelsmiller K, Wei J, Bauernfeind F, Ellermeier J, Kisser U, Bauer CA, Dauer M, Eigler A, Maraskovsky E, Endres S, Schnurr M (2011) An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma. Int J Cancer 128(4):897-907. doi:10.1002/ijc.25399
21. Rotzschke O, Falk K, Stevanovic S, Jung G, Walden P, Rammensee HG (1991) Exact prediction of a natural T cell epitope. Eur J Immunol 21(11):2891-2894
22. Bloom MB, Perry-Lalley D, Robbins PF, Li Y, el-Gamil M, Rosenberg SA, Yang JC (1997) Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 185(3):453-459 (Pubitemid 27078363)
23. Yang JC, Perry-Lalley D (2000) The envelope protein of an endogenous murine retrovirus is a tumor-associated T-cell antigen for multiple murine tumors. J Immunother 23(2):177-183 (Pubitemid 30165166)
24. Heckelsmiller K, Beck S, Rall K, Sipos B, Schlamp A, Tuma E, Rothenfusser S, Endres S, Hartmann G (2002) Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. Eur J Immunol 32(11):3235-3245 (Pubitemid 35414881)
25. Martins I, Tesniere A, Kepp O, Michaud M, Schlemmer F, Senovilla L, Seror C, Metivier D, Perfettini JL, Zitvogel L, Kroemer G (2009) Chemotherapy induces ATP release from tumor cells. Cell Cycle 8(22):3723-3728
26. Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, Kroemer G (2010) Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res 16(12):3100-3104. doi:10.1158/1078-0432.CCR- 09-2891
27. Kang TH, Mao CP, Lee SY, Chen A, Lee JH, Kim TW, Alvarez R, Roden RB, Pardoll DM, Hung CF, Wu TC (2013) Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res. doi:10.1158/0008-5472.CAN- 12-4241
28. Kim HS, Park HM, Park JS, Sohn HJ, Kim SG, Kim HJ, Oh ST, Kim TG (2010) Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model. Vaccine 28(49):7787-7796. doi:10.1016/j.vaccine.2010.09.046
29. Nowak AK, Robinson BW, Lake RA (2002) Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res 62(8):2353-2358 (Pubitemid 34411717)
30. Le HK, Graham L, Cha E, Morales JK, Manjili MH, Bear HD (2009) Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol 9(7-8):900-909. doi:10.1016/j.intimp. 2009.03.015
31. Mundy-Bosse BL, Lesinski GB, Jaime-Ramirez AC, Benninger K, Khan M, Kuppusamy P, Guenterberg K, Kondadasula SV, Chaudhury AR, La Perle KM, Kreiner M, Young G, Guttridge DC, Carson WE III (2011) Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Cancer Res 71(15):5101-5110. doi:10.1158/0008-5472.CAN-10-2670
32. Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH (2007) Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 67(19):9518-9527. doi:10.1158/0008-5472.CAN-07-0175 (Pubitemid 47535942)
33. Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ, Vonderheide RH (2012) Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21(6):822-835. doi:10.1016/j.ccr.2012.04.025
34. Bruchard M, Mignot G, Derangere V, Chalmin F, Chevriaux A, Vegran F, Boireau W, Simon B, Ryffel B, Connat JL, Kanellopoulos J, Martin F, Rebe C, Apetoh L, Ghiringhelli F (2013) Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 19(1):57-64. doi:10.1038/nm.2999
35. Ghansah T, Vohra N, Kinney K, Weber A, Kodumudi K, Springett G, Sarnaik AA, Pilon-Thomas S (2013) Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma. Cancer Immunol Immunother 62(6):1083-1091. doi:10.1007/s00262-013-1407-9
36. Shevchenko I, Karakhanova S, Soltek S, Link J, Bayry J, Werner J, Umansky V, Bazhin AV (2013) Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. Int J Cancer 133(1):98-107. doi:10.1002/ijc.27990
37. Kan S, Hazama S, Maeda K, Inoue Y, Homma S, Koido S, Okamoto M, Oka M (2012) Suppressive effects of cyclophosphamide and gemcitabine on regulatory T-cell induction in vitro. Anticancer Res 32(12):5363-5369
38. Tan MC, Goedegebuure PS, Belt BA, Flaherty B, Sankpal N, Gillanders WE, Eberlein TJ, Hsieh CS, Linehan DC (2009) Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol 182(3):1746-1755
39. Dauer M, Herten J, Bauer C, Renner F, Schad K, Schnurr M, Endres S, Eigler A (2005) Chemosensitization of pancreatic carcinoma cells to enhance t cell-mediated cytotoxicity induced by tumor lysate-pulsed dendritic cells. J Immunother 28(4):332-342 (Pubitemid 40962326)
40. Gelbard A, Garnett CT, Abrams SI, Patel V, Gutkind JS, Palena C, Tsang KY, Schlom J, Hodge JW (2006) Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. Clin Cancer Res 12(6):1897-1905. doi:10.1158/1078-0432.CCR-05-1761
41. Gameiro SR, Caballero JA, Higgins JP, Apelian D, Hodge JW (2011) Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses. Cancer Immunol Immunother 60(9):1227-1242. doi:10.1007/s00262-011- 1020-8
42. Takahara A, Koido S, Ito M, Nagasaki E, Sagawa Y, Iwamoto T, Komita H, Ochi T, Fujiwara H, Yasukawa M, Mineno J, Shiku H, Nishida S, Sugiyama H, Tajiri H, Homma S (2011) Gemcitabine enhances wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response. Cancer Immunol Immunother 60(9):1289-1297. doi:10.1007/s00262-011-1033-3
43. Ishizaki H, Manuel ER, Song GY, Srivastava T, Sun S, Diamond DJ, Ellenhorn JD (2011) Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model. Cancer Immunol Immunother 60(1):99-109. doi:10.1007/s00262-010- 0923-0